Grandfield & Dodd LLC Sells 405 Shares of Johnson & Johnson $JNJ

Grandfield & Dodd LLC trimmed its position in Johnson & Johnson (NYSE:JNJ) by 0.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 109,652 shares of the company’s stock after selling 405 shares during the quarter. Grandfield & Dodd LLC’s holdings in Johnson & Johnson were worth $16,749,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Donoghue Forlines LLC increased its holdings in shares of Johnson & Johnson by 6.2% in the second quarter. Donoghue Forlines LLC now owns 9,488 shares of the company’s stock worth $1,449,000 after purchasing an additional 554 shares during the period. Oak Harvest Investment Services grew its position in Johnson & Johnson by 1.6% during the second quarter. Oak Harvest Investment Services now owns 54,549 shares of the company’s stock worth $8,332,000 after buying an additional 844 shares in the last quarter. Banco Bilbao Vizcaya Argentaria S.A. increased its stake in Johnson & Johnson by 0.8% in the 2nd quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 201,848 shares of the company’s stock worth $30,822,000 after acquiring an additional 1,600 shares during the last quarter. Hibernia Wealth Partners LLC purchased a new stake in shares of Johnson & Johnson in the 2nd quarter valued at about $314,000. Finally, W.H. Cornerstone Investments Inc. boosted its position in shares of Johnson & Johnson by 0.7% during the 2nd quarter. W.H. Cornerstone Investments Inc. now owns 7,896 shares of the company’s stock valued at $1,206,000 after acquiring an additional 58 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on JNJ. Johnson Rice set a $190.00 price objective on shares of Johnson & Johnson and gave the stock a “hold” rating in a research report on Wednesday, October 22nd. Stifel Nicolaus increased their price target on shares of Johnson & Johnson from $165.00 to $190.00 and gave the stock a “hold” rating in a report on Wednesday, October 15th. Barclays lifted their price objective on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an “equal weight” rating in a report on Thursday, July 17th. Guggenheim raised Johnson & Johnson from a “neutral” rating to a “buy” rating and increased their target price for the company from $167.00 to $206.00 in a research note on Tuesday, September 23rd. Finally, Daiwa America raised Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 20th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $200.52.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Performance

Johnson & Johnson stock opened at $195.19 on Friday. The firm has a fifty day simple moving average of $185.46 and a two-hundred day simple moving average of $169.66. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $196.00. The company has a market capitalization of $470.27 billion, a PE ratio of 18.84, a P/E/G ratio of 2.19 and a beta of 0.38.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The firm had revenue of $24.02 billion for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. Research analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio is 50.19%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.